CALC Stock — CalciMedica Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates target calcium release-activated calcium (“CRAC”) channels and, if approved, would represent a new class of therapeutics.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.36

Market cap

$9.3M

Cash

$18.6M

Enterprise value

-$9.3M

Balance sheet

Cash	$18.6M
Debt	$0.0M
Net cash	$18.6M
Enterprise value	-$9.3M
Basic shares	34.1M shares
Fully diluted shares	48.6M shares
Fully diluted market cap	$66.1M
Cash per share	$0.55
Quarterly burn	$4.6M
Cash runway	4.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

34.1M

Pre-funded warrants

0.0M

Options

5.6M

RSUs

0.0M

Warrants

8.4M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.4M

FDSO

48.6M

Cap table as of 2026-06-30.

Price history

Loading CALC daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

Auxora

Phase 2 · Active Modality: small molecule (IV)

Aliases CM4620

Target CRAC channels

Partnerships not disclosed

Indications

Acute pancreatitis (AP) (Phase 2)
Pulmonary arterial hypertension (PAH) (Phase 1)
Pediatric asparaginase-induced pancreatic toxicity (AIPT) (Phase 2)
Acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF) (Phase 2)
Severe COVID-19 pneumonia (Phase 2)

Catalysts

— None
— None
— None

Status note Active ingredient is zegocractin (formerly CM4620). Completed Phase 2b CARPO in AP. KOURAGE Phase 2 in AKI/AHRF discontinued January 2026; no current plans to resume AKI dosing. Initiation of next AP trial subject to obtaining additional financing; going-concern warning disclosed.

CM5480

Preclinical · Active Modality: small molecule (oral)

Target CRAC channels

Partnerships not disclosed

Indications

Pulmonary arterial hypertension and other chronic pulmonary hypertension (Preclinical)

Catalysts

— None

Status note Selective oral CRAC channel inhibitor in IND-enabling development for PAH. Exploratory preclinical work in chronic pancreatitis, rheumatoid arthritis, ulcerative colitis and allergic asthma.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04195347	Phase 2	Recruiting	Collaborator	St. Jude Children's Research Hospital	—	Acute Pancreatitis	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for St. Jude Children's Research Hospital on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	622,432	+622,432	0.41%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CALC — CalciMedica Inc. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Active clinical trials

Specialist fund holders

Latest news

CALC — CalciMedica Inc.